Sign in
Not yet taking people in FrancePhase 2

Shorter waiting time for Hexvix blue light imaging in bladder cancer

Tests whether Hexvix lights up bladder tumors well after a shorter wait.

Key facts

Who runs it
Institut Paoli Calmettes
Where
Marseille, FranceSee the site
Registry title
Hex-SUB1-IPC 2025-067 - PROOF OF CONCEPT: FEASIBILITY OF PHOTODYNAMIC DIAGNOSIS IN BLADDER CANCER PATIENTS WITH SUB-ONE-HOUR INSTILLATION TIME OF HEXAMINOLEVULINATE (HEXVIX®)
Status
Not yet recruiting
Phase
Phase 2
People taking part
50 people, planned
Started
6 Nov 2026
Expected to end
6 Oct 2027
Type of study
Interventional
Record updated
30 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a bladder tumour of the papillary type, first-time or returned, who are scheduled for tumour removal through the urethra (TURB) with Hexvix®. It tests blue light cystoscopy started 30 minutes after Hexvix® is put into the bladder.

Age
Over 18 years
Sex
Men and women
Disease stage
First-time or recurrent papillary bladder cancer, confirmed by cystoscopy or imaging, scheduled for TURB with Hexvix®.
Earlier treatment
No previous pelvic radiotherapy. No recent treatment placed in the bladder (BCG or chemotherapy).

Main reasons for not taking part

  • Flat lesion without a papillary tumour
  • Tumour that has grown into the bladder muscle, with maximal TURB before radio-chemoradiotherapy
  • Previous diagnosis of porphyria, or hypersensitivity to hexaminolevulinate hydrochloride or its excipients
  • Pregnant or breastfeeding women, or women who may become pregnant without effective contraception
  • Urethral stricture, or a bladder that cannot hold the Hexvix® solution

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • man/woman above 18 years
  • primary or recurrent papillary bladder cancer confirmed by cystoscopy or imaging, scheduled for TURB with Hexvix®
  • Covered by a Healthcare System
  • Signed informed consent obtained prior to initiation of any study-specific procedures and treatment as confirmation of the patient’s awareness and willingness to comply with the study requirements

Who cannot take part

  • Cystoscopy or bladder biopsies performed without previously identified tumor lesions
  • Previous diagnosis of porphyria
  • Maximal TURB for muscle-invasive bladder tumor (prior to radio-chemoradiotherapy)
  • Other TURB procedures not requiring prior Hexvix® instillation
  • Previous pelvic radiotherapy
  • Bladder inflammation related to chronic urinary tract infection or mechanical irritation of the bladder mucosa due to indwelling catheter or recent intravesical treatment (BCG or chemotherapy)
  • Any severe uncontrolled medical condition considered by the investigator as a contraindication for using tested product
  • Hypersensitivity to the active substance hexaminolevulinate hydrochloride or to any of the excipients listed in section 6.1. of the SmPC
  • Vessie peu compliante / capacité vésicale insuffisante ne permettant pas de retenir le Hexvix
  • Adults under legal protection (guardianship, curatorship, or judicial protection)
  • Inability to comply with the medical follow-up of the trial for geographical, social, or psychological reasons
  • Flat lesion without papillary tumor associated
  • Urethral stricture
  • Pregnant women or those who may become pregnant (without effective contraception) or breastfeeding

Where in France

  • Institut Paoli-CalmettesMarseille, FranceNot yet recruiting

About the trial

What the trial wants to find out

The main objective is to evaluate the quality of tumor fluorescence by Hexvix® when the blue light cystoscopy is started 30 min after the timepoint of instillation of Hexvix® into the bladder.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Hex-SUB1-IPC 2025-067 - PROOF OF CONCEPT: FEASIBILITY OF PHOTODYNAMIC DIAGNOSIS IN BLADDER CANCER PATIENTS WITH SUB-ONE-HOUR INSTILLATION TIME OF HEXAMINOLEVULINATE (HEXVIX®)
Plain-language title
Shorter waiting time for Hexvix blue light imaging in bladder cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
30 September 2026